×
English
हिंदी
ગુજરાતી
Home
My Feed
Remove Ads
Get Premium Content
Go Pro @₹99
Credit Cards
Instant Loans
Apply Now
Credit Score
Refer & Earn ₹500
Refer Now
Finance Tracker
Learning Curve
Fixed Deposits
Business Loan
Markets
Markets
FII & DII Activity
Corporate Action
Investment Advice
Earnings
Technical Trends
Stock Deals
Intraday Large Deals
Bonds
Webinar
Pre Market
Stock Scanner
Sector Analysis
Unlisted Shares
Monsoon Tracker
Seasonality Analysis
Crypto Dashboard
Web Stories
Tax Calculator
Swing Trading Masterclass
Forum
Gold Rate
Silver Rate
IFSC Code Finder
Storyboard18
IPO
Economic Indicators
Economic Calendar
Global Markets
US Markets
ETFs
Indian Indices
News
News
Tech/Startups
Auto
Research
Opinion
Politics
Personal Finance
EPF Guide
Real Estate
Portfolio
Watchlist
Personal Finance
Personal Finance
Loans
Fixed Deposit Comparison
Fixed Deposit Interest Calculator
Moneycontrol - SecureNow Health Insurance ratings
Mutual Funds
Mutual Funds
Performance Tracker
Top ranked funds
My Portfolio
Top performing Categories
Forum
New Fund Offers
MF Simplified
Commodities
Mutual Funds
Gold Rate
Silver Rate
Currencies
Cryptocurrency
Media
Live TV & Shows
Video
Podcast
Photos
Invest Now
Trade like Experts
Specials
Pharma Industry Conclave
Unlocking opportunities in Metal and Mining
Mutual Fund Summit 2025
Advanced Technical Charts
International
Get App
Be a
Pro
Home
PRO
Markets
News
Editor’s Picks
Tech
India
Learning Curve
Portfolio
Watchlist
Commodities
MF
Personal Finance
Forum
Videos
you are here:
Home
News
Ads
Dr. Lal PathLabs Q2 PAT seen up 28.4% YoY to Rs 112 cr: Prabhudas Lilladher
Dr. Lal PathLabs Q3 PAT seen up 27.4% YoY to Rs. 54.1 cr: Prabhudas Lilladher
Dr Lal Pathlabs Q2 PAT seen up 48.8% YoY to Rs. 84.8 cr: Kotak
Dr Lal Pathlabs Q1 PAT seen up 17.6% YoY to Rs. 58.1 cr: Kotak
Dr. Lal PathLabs Q1 PAT seen up 5.5% YoY to Rs. 52.1 cr: Prabhudas Lilladher
Dr Lal Pathlabs Q4 PAT seen up 28.3% YoY to Rs. 51.4 cr: Kotak
Dr. Lal Pathlabs Q4 PAT seen up 26.2% YoY to Rs. 50.6 cr: Prabhudas Lilladher
Brokerages remain mixed on Dr Lal PathLabs Q2 show; Citi maintains buy rating
Dr Lal Pathlabs Q1 PAT seen up 13.3% YoY to Rs. 50.1 cr: Kotak
Dr. Lal Pathlabs Q4 PAT seen up 19.7% YoY to Rs 37.5 cr: Edelweiss
Competitive pricing leads to higher volume growth, says Dr Lal Pathlabs
Expect 26-27% margins for full year; Q3, Q4 to be good on low base: Dr Lal PathLabs
Dr Lal Pathlabs Q2 PAT may dip 0.9% YoY to Rs. 52 cr: Kotak
Acquisition in Bangladesh is minor, won't impact FY18 numbers: Dr Lal Pathlab
Volume performance to improve going ahead: Dr Lal PathLabs
Dr. Lal Pathlabs Q4 PAT seen up 30.8% to Rs 40.4 cr: ICICI Securities
Dr Lal PathLabs to start Kolkata operations next year
Dr. Lal Pathlab Q3 PAT may dip 20% to Rs 42 cr: ICICI Securities
Dr Lal PathLabs sees margins declining 200-300 bps in 2-3 yrs
Dr Lal PathLabs expects good volumes in Q2
Confident of beating sector growth of 16-17%: Dr Lal PathLabs
May outperform industry's 17% FY17 growth rate forecast: Dr Lal
Expect margins to be in range of 25-26%: Dr Lal Pathlabs
Home
Markets
Loans
SPIN
2
WIN
News
Portfolio